Ranibizumab biosimilar - Xbrane

Drug Profile

Ranibizumab biosimilar - Xbrane

Alternative Names: Xlucane

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xbrane
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Age-related macular degeneration; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema

Most Recent Events

  • 16 Jul 2018 Xbrane and STADA Arzneimittel agree to co-develop Ranibizumab biosimilar (Xlucane)
  • 16 Jul 2018 Xbrane plans a phase II/III trial for Age-related macular degenration
  • 21 Dec 2017 Xbrane Biopharma expects to sign a final agreement with potential partners regarding out-licensing of ranibizumab biosimilar in China during the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top